A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost biosimilar version of it is slated to hit the market this year.

Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes ...

AbbVie sues HHS over Botox Medicare pricing, challenging CMS authority under the Inflation Reduction Act and drug price negotiation rules.

AbbVie Inc. is challenging the Trump administration’s decision to select its Botox drug for a government program that slashes ...

The Centers for Medicare & Medicaid Services just announced the next 15 brand-name medicines selected for Medicare’s drug price negotiation program, which mandates price reductions of at least 25%.

In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming price cuts under the Inflation Reduction Act (IRA), AbbVie is the late | The ...

AbbVie (ABBV) stock is in focus as the company files lawsuit over Medicare's decision to select its Botox therapy for prciing negotiations. Read more here.

KFF Biden era law improves Medicare Part D coverage for high-cost drugs ahead of 2026 price negotiations, enhancing patient access nationwide.

AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a plasma-derived product.

Social Security and Medicare are by far the biggest contributors to our national debt. The federal government spent $1.6 ...

In today’s issue: Our in-depth WP Intelligence report on Medicaid’s new approach to innovative yet pricey drugs. Botox ...

The federal government has expanded its drug price negotiation program for seniors, adding more than a dozen high-cost medicines ...